Half-dose photodynamic therapy offers robust anatomic improvement for patients with acute central serous chorioretinopathy.

Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was ...

Dr Tim Cooksley, a consultant in acute medicine, says the Prime Minister risks an 'eternal crisis' in the NHS without urgent ...

As India logs 5 cases of HMPV, here's all you need to know about how human metapneumovirus is different from Covid-19 and ...

What is HMPV?The discovery of human metapneumovirus, or HMPV, goes back to 2000, when a group of Dutch scientists set out to ...

By Karen Roman Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of ...

The trial is designed to assess the tolerability, efficacy, and safety of two different dosages of the therapy.